Karolinska Development (KDV.ST) Stock Price

Karolinska Development Price

OMX·CLOSED
0.00
​
Market closed

Karolinska Development stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Karolinska Development business model & stock analysis

Karolinska Development AB is a Swedish investment company focused on promoting innovative biotech companies and start-ups. The company was founded in 2003 by the government of the Stockholm region and Karolinska Institutet University. The business model of Karolinska Development is designed to make profitable investments in promising biotech companies. It specifically supports companies in the areas of cancer treatment, immunotherapy, cardiovascular diseases, as well as neurology and psychiatry. The company provides capital and expertise to turn promising innovations into successful products. Karolinska Development operates different divisions to fulfill this purpose, including Karolinska Development AB (parent company), Karolinska Development Life Science Venture AB (a specialized investment company), and Karolinska Development Management AB (portfolio management team). Karolinska Development has built a strong portfolio of companies developing innovative products and therapies. One example is Modus Therapeutics AB, which has developed a new therapy for the treatment of sickle cell anemia. Another example is Aprea AB, a developer of gene therapies for combating cancer using tumor cells and genetic sequencing. The company's history is marked by many successful investments and acquisitions. One example is the acquisition of BioChromix AB in 2012, which developed a new technology for rapid and precise diagnosis of infectious diseases. Karolinska Development also actively participates in supporting new start-ups and company formations to promote promising innovations. Karolinska Development AB plays an important role in the biotech industry and significantly supports research in drug development. Through its unique position as an investor and partner for innovative companies, Karolinska Development is a driving force in the field of biotechnology. The company's business field is characterized by high risk and requires strategic thinking and skillful maneuvering in the market. However, Karolinska Development has managed to build a solid foundation and establish itself as an important player in the biotech industry through targeted investments, acquisitions, and partnerships. In summary, Karolinska Development plays a vital role in the biotech industry in Sweden and worldwide. The company has produced many innovative companies and products through targeted investments and acquisitions, contributing to changing lives and combating diseases. With its unique position as an investor and partner for biotech companies, Karolinska Development is well-equipped to continue promoting new innovations and advancing drug development in the future.

Frequently asked questions about Karolinska Development

Karolinska Development AB operates as a life sciences investment company. The company's business model focuses on identifying, developing, and commercializing innovative healthcare technologies originating from leading academic research institutions in the Nordic region. Karolinska Development AB aims to support the growth of these projects by providing expertise, funding, and strategic guidance. By actively participating in the development process, the company strives to maximize the potential value of its portfolio of companies. Through partnerships and collaborations, Karolinska Development AB aims to advance medical innovations that address significant unmet medical needs, ultimately benefiting both patients and investors.

Karolinska Development AB is primarily active in the life sciences and healthcare industries.

The main competitors of Karolinska Development AB in the market include other biotechnology and pharmaceutical companies focusing on innovation and drug development. Some notable competitors include AstraZeneca, Novartis, Pfizer, GlaxoSmithKline, and Johnson & Johnson. These companies compete in the same industry, striving to bring new drugs and therapies to the market. Karolinska Development AB sets itself apart through its expertise in evaluating and identifying promising early-stage life science opportunities.

Karolinska Development AB is a leading investment company in the field of life sciences. Established in 2003, the company focuses on identifying and developing innovative pharmaceutical products and medical technologies. As a subsidiary of Karolinska Institutet Holding AB, Karolinska Development collaborates with academia, top-notch experts, and industry stakeholders to bring promising research and commercialize breakthrough innovations. The company's portfolio includes a diverse range of investments in companies involved in drug development, medical devices, diagnostics, and digital health solutions. Karolinska Development aims to leverage its extensive network and knowledge to drive the growth and success of its portfolio companies in the global healthcare market.

Karolinska Development AB, a leading Nordic life science investment company, has achieved several significant milestones. The company has successfully supported the growth of numerous innovative healthcare companies and fostered collaborations with top academic institutions. Karolinska Development has enabled the development and commercialization of several breakthrough therapies and medical technologies, addressing critical unmet medical needs. Its extensive portfolio encompasses companies focusing on various therapeutic areas, including oncology, rare diseases, and regenerative medicine. With its strategic investments and valuable expertise, Karolinska Development continues to play a vital role in advancing the life sciences industry and improving patient outcomes.

Karolinska Development AB, a renowned Swedish life science investment company, primarily operates in Sweden. With its headquarters situated in Stockholm, the company focuses on identifying and developing innovations within the healthcare sector. Karolinska Development AB plays a crucial role in supporting the commercialization and growth of early-stage life science companies originating from Sweden's prestigious Karolinska Institutet. With an extensive network of contacts and partnerships, Karolinska Development AB drives advancements in the field of biomedicine, primarily within Sweden's vibrant life science ecosystem.

Karolinska Development AB represents a value-driven corporate philosophy focused on enabling the commercialization of innovative life science technologies. The company is dedicated to improving human health and actively supports the development of breakthrough therapies and medical innovations. Karolinska Development AB strives for long-term financial success while prioritizing ethical and sustainable practices. By identifying promising projects and providing strategic guidance, funding, and industry expertise, the company accelerates the growth of healthcare companies and fosters collaborations within the life science sector. Karolinska Development AB's commitment to driving scientific advancements and delivering shareholder value positions it as a leading player in the industry.

Converted at the current exchange rate, the Karolinska Development share trades at 0.00 EUR (0.00 SEK).

The Karolinska Development share (KDV.ST) is listed on 6 stock exchanges, including: London (0P3C.L), Frankfurt (2I9.F), München (2I9.MU), Stockholm (KDEV.ST).

Karolinska Development AB specializes in the development of medications and medical technologies. The company's business model is based on building partnerships with promising startups and research institutions in the healthcare sector and supporting them in bringing their products and technologies to market. The company operates in four strategic business areas: company formation, technology development, product development, and management consulting. Karolinska Development AB aims to become a leading company in the healthcare industry and promote the development of medications and medical technologies.

The revenue cannot currently be calculated for Karolinska Development.

The profit cannot currently be calculated for Karolinska Development.

The P/E ratio cannot be calculated for Karolinska Development at the moment.

The P/S cannot be calculated for Karolinska Development currently.

The Eulerpool Quality Score for Karolinska Development is 2/10.

The ISIN of Karolinska Development is SE0002190926. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Karolinska Development is A0M84G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Karolinska Development is KDV.ST. The ticker symbol is used to trade Karolinska Development shares on the stock exchange.

Fair ValueTerminal
0.00 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Apr 15, 2011
ISIN
SE0002190926
Cusip
W50064125
Sedol
B3FPFG1
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
—
ROA (Return on Assets)
—
ROCE (Return on Capital Employed)
—
ROIC (Return on Invested Capital)
—
Last updated Nov 22, 2026, 3:55 PM

Karolinska Development Peer Group

Karolinska Development Ticker

FRANKFURT · 2I9.FLONDON · 0P3C.LMUNICH · 2I9.MUOTC · KDEVFSTOCKHOLM · KDEV.STSTOCKHOLM · KDEV.ST

Karolinska Development FIGI

KDEV:SS · BBG001MKRLW7KDEV:EU · BBG001VDBD49KDEV:EO · BBG004P8CWR3KDEV:XH · BBG004P8CWV8KDEV:XF · BBG004P8CWX6KDEV:XE · BBG004P8CWZ4KDEV:XJ · BBG004P8CX00KDEV:XL · BBG004P8CX19KDEV:XG · BBG004P8CX28KDEV:XO · BBG004P8CX37KDEV:XS · BBG004P8CX73KDEV:XA · BBG004P8CX91

All fundamentals and in-depth analysis of Karolinska Development

Our stock analysis for Karolinska Development stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karolinska Development. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.